IMMUNOPRECISE ANTIBODIES
IPA is a single source provider of services for the complete antibody discovery value chain. We offer the most comprehensive collection of antibody discovery platforms in the industry, combined with state of the art lead candidate optimization and characterization. This allows us to assist clients from the moment they identify a therapeutic target to the preparation of applying for investigation review of the clinical product. ImmunoPrecise operates from state of the art laboratory facilities lo... cated at the Vancouver Island Technology Park in Victoria, British Columbia which house its tissue culture and molecular facilities as well as an animal care unit, and is a member of the Canadian Council for Animal Care and in association with U-Protein Express B.V. its subsidiary laboratory operation in Life Science Incubator, Utrecht Science Park, Utrecht, the Netherlands. The services offered to customers include the development of wild-type and humanized mouse and rat monoclonal antibodies and recombinant rabbit monoclonal antibodies against a wide spectrum of antigens, as well as polyclonal antibodies, immunologically-based assays, recombinant protein manufacturing, and advanced solutions to challenges faced by clients in antibody-related research and development. In addition, cryopreservation services are provided for the storage of valuable biological materials including hybridoma clones, plasmid constructs, and cell lines. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications. ImmunoPrecise employs a highly experienced group of R&D scientists. Over the last 25 years, investments in innovative and proprietary technologies and methods have vastly improved the speed and efficiency of monoclonal and polyclonal antibody production.
IMMUNOPRECISE ANTIBODIES
Industry:
Biotechnology
Founded:
1989-01-01
Address:
Victoria, British Columbia, Canada
Country:
Canada
Website Url:
http://www.immunoprecise.com
Total Employee:
11+
Status:
Active
Contact:
1-250-483-0308
Email Addresses:
[email protected]
Total Funding:
38.98 M USD
Technology used in webpage:
SPF Mobile Non Scaleable Content Euro Microsoft Exchange Online Amazon Office 365 Mail IPv6 Microsoft Azure DNS GoDaddy DNS IIS
Current Employees Featured
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2022-03-29 | BioStrand | BioStrand acquired by ImmunoPrecise Antibodies | 20 M EUR |
2018-04-06 | ModiQuest B.V. | ModiQuest B.V. acquired by ImmunoPrecise Antibodies | 11.2 M CAD |
2017-08-23 | U-Protein Express | U-Protein Express acquired by ImmunoPrecise Antibodies | N/A |
Investors List
North Dakota Department of Agriculture
North Dakota Department of Agriculture investment in Grant - ImmunoPrecise Antibodies
Brisio Innovations
Brisio Innovations investment in Private Equity Round - ImmunoPrecise Antibodies
Key Employee Changes
Date | New article |
---|---|
2021-08-04 | ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans |
Official Site Inspections
http://www.immunoprecise.com
- Host name: 199.60.103.145
- IP address: 199.60.103.145
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto

More informations about "ImmunoPrecise Antibodies"
Company Information | IPA - ipatherapeutics.com
The dynamic duo for antibody discovery. Simply the best combined wet lab + in silico antibody discovery. Recently ranked by one of the pharmaceutical industry’s most trusted independent market research sources with the highest score for …See details»
IPA (ImmunoPrecise Antibodies) - LinkedIn
IPA (ImmunoPrecise Antibodies) | 6,439 followers on LinkedIn. HUB of biotherapeutic intelligence | IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of ...See details»
Single source provider of full-service therapeutic antibody …
ImmunoPrecise Antibodies - Vancouver Island Technology Park …
ImmunoPrecise Antibodies Ltd (IPA) is a full-service, therapeutic antibody discovery company offering species agnostic advancements such as the B cell Select™ single-cell interrogation …See details»
Single source provider of full-service therapeutic antibody …
ImmunoPrecise is a full-service therapeutic antibody company focused on next-generation antibody discovery. ImmunoPrecise operates from state- ... organization for multiple …See details»
ImmunoPrecise Antibodies Advances Therapeutic Innovation with ...
Sep 26, 2024 This achievement underscores IPA’s leadership as a Contract Research Organization creating high-quality therapeutic antibodies, while pioneering work in the field of …See details»
IPA (ImmunoPrecise Antibodies) - Crunchbase
IPA (ImmunoPrecise Antibodies) closed its last funding round on Jan 27, 2025 from a Post-IPO Equity round. Who are IPA (ImmunoPrecise Antibodies) 's competitors? Alternatives and possible competitors to IPA (ImmunoPrecise …See details»
IPA Adds MA Office | ImmunoPrecise Antibodies
Feb 14, 2019 ImmunoPrecise Antibodies Ltd is a Canadian contract research organization providing a range of services, including antibody discovery, manufacturing, optimization, …See details»
ImmunoPrecise | Scientist.com
Mar 6, 2021 What problems does your organization solve? We offer innovative, adaptable solutions for generating and selecting antibodies against challenging targets. We also bring …See details»
ImmunoPrecise Antibodies Ltd. (IPA) - Yahoo Finance
See the company profile for ImmunoPrecise Antibodies Ltd. (IPA) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
IPA Company Profile - Office Locations, Competitors, Revenue
Oct 29, 2024 IPA (ImmunoPrecise Antibodies) is a therapeutic antibody discovery company. It offers target analysis and immunization, antibody discovery and characterization, …See details»
ImmunoPrecise Antibodies Advances Therapeutic Innovation with ...
VICTORIA, British Columbia--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), ImmunoPrecise Antibodies Ltd. (the “Company” or …See details»
ImmunoPrecise Antibodies Ltd. Announces Key Board and Board …
Nov 27, 2023 ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call November 27, 2023 …See details»
ImmunoPrecise Antibodies - VentureRadar
ImmunoPrecise is a full-service, therapeutic antibody discovery company offering species agnostic advancements such as the B cell Select™ single-cell interrogation technology, …See details»
Single source provider of full-service therapeutic antibody …
ImmunoPrecise Antibodies (IPA) is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover …See details»
NSERC Awards Grant to Fund Collaboration Between …
May 27, 2020 ImmunoPrecise is a full-service, antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human …See details»
Immunoprecise Antibodies in Therapeutic Research
Mar 20, 2025 Immunoprecise antibodies stand out for their heightened specificity, binding affinity, and reduced cross-reactivity. Unlike conventional monoclonal antibodies that may …See details»
ImmunoPrecise Reports Financial Results and Recent Business …
Jul 29, 2022 An operator will register your name and organization. ... ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a biotherapeutic, innovation-powered company that …See details»
ImmunoPrecise Lands $10M Strategic Partnership Amid Mixed Q3 …
19 hours ago ImmunoPrecise Antibodies (IPA) reported Q3 FY25 financial results, securing an $8-10M strategic partnership for co-developing Antibody-Drug Conjugates and bispecific …See details»
B-Cell Facility Opens | ImmunoPrecise Antibodies
Apr 27, 2018 Victoria, British Columbia, Canada, April 27, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) …See details»